An interventional study of Boracare remote monitoring solution in COPD, sponsored by Biosency. Recruiting at 10 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.
Sponsored by Biosency · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France — 71 open to participants now, 81 under way, 10 of them phase 3. Pulmonary Disease, Chronic Obstructive · France.
Among the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France, this one is the 97th largest by planned enrollment of the 286 interventional ones that give a count, is one of 18 that started in 2024, is one of 158 with no phase, reaches primary completion later than 49 of the 80 other live ones, and was the 363rd registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →71 of the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France are open now. Recruiting first, the newest first:
Fondation Hôpital Saint-Joseph · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
Eli Lilly and Company · Sites in France, United States, Argentina and 15 more countries
Ages 40–75
CHU de Reims · Sites in France
Ages 18+
Groupe Hospitalier du Havre · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
406 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 84 · Phase 4 20
First in 2000; this study’s year is marked. 18 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 380 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 138 across the 286 interventional studies, 100 across the 119 observational. Of the 299 that completed or were terminated, 70 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
136 of 406 have an industry lead sponsor. The 10 most frequent:
Biosency is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Biosency has 2 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
16 of the studies in Pulmonary Disease, Chronic Obstructive with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT05844462Phase 3Assistance Publique - Hôpitaux de ParisTadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease | 2027-10 |
| NCT07125989Centre Hospitalier Universitaire de Saint EtienneEffect of Exercise Ventilatory Support Pressure on Endurance in Patients With Severe Chronic Obstructive Pulmonary Disease - AVE-BPCO | 2027-01 |
| NCT04339270University Hospital, MontpellierChronic Airway Disease, Mucus Rheology and Exacerbations | 2027-02 |
| NCT06653933University Hospital, GrenobleStudy of Sleep Quality in the Intensive Care Unit and Association with Weaning from Invasive Ventilation in Patients with Chronic Obstructive Bronchopneumopathy. | 2027-02-01 |
Add all 16 to your calendar (.ics) → With an account.
Among the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to demonstrate the superiority of remote monitoring with the Bora Care solution in patients with COPD and frequent exacerbations (experimental group) compared to conventional follow-up alone (control group) on the total number of hospital days per patient for respiratory deterioration over 12 months of follow-up.
The main question it aims to answer is: Does remote monitoring of COPD patients reduce the average annual length of hospitalization for exacerbations of COPD patients?
All participants will benefit a conventional clinical follow-up.
Participants in experimental group will also benefit from the Bora care remote monitoring system.
Control group (control): conventional follow-up For the target population (frequent exacerbating COPD patients), the usual follow-up includes two consultations with the general practitioner and one consultation with the pulmonologist per year. The inclusion and follow-up visit at 12 months by a pulmonologist are consistent with the follow-up of COPD patients in current practice and the recommendations of HAS (National Authority for Health) and SPLF (French-Language Society of Pneumology).
Experimental group (conventional monitoring + remote monitoring):
The patients will be subject to conventional clinical follow-up and at the same time benefit from the Bora care remote monitoring system. The Bora care remote monitoring system includes a BoraBand wristband measuring vital signs at home, the Bora Connect platform for caregiver visualization of data and the BVS3 score for early detection of COPD exacerbations. Patients are monitored daily remotely by Case Managers (nurses trained in Bora Care solution), who, when the BVS3 > 3 alert is triggered on Bora Connect, call the patient to inform the patient about his symptoms, then alert the pulmonologist by transmitting the information from Bora Connect and the minutes of the phone call, who, according to conventional management, decides whether or not to hospitalize the patient, or to generate an unscheduled consultation in order to prescribe drug treatment, and/or to prescribe additional examinations, and/or to adapt the patient's oxygen therapy prescription.
The Case Manager re-evaluates the situation after 48 hours and 96 hours if necessary and forwards the information to the pulmonologist. The nature of the transmission of information (telephone or email) between the Case Manager and the pulmonologist in case of an alert is defined when the patient is included by the pulmonologist. If desired, remotely monitored patients will be able to access the Bora Connect interface provided for patients (restricted viewing of data).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Conventional follow-up: two consultations with the general practitioner and one consultation with the pulmonologist per year. The inclusion and follow-up visit at 12 months by a pulmonologist are consistent with the follow-up of COPD patients in current practice and the recommendations of SAH and SPLF.
Patients will receive conventional clinical follow-up and at the same time benefit from the Bora care remote monitoring system. Patients are monitored daily remotely by Case Managers, who, when the BVS3-3 alarm is triggered on Bora Connect, call the patient to inform the patient about his symptoms, then notify the pulmonologist by transmitting the information from Bora Connect and the minutes of the phone call, who, according to conventional management, decides whether or not to hospitalize the patient, or to generate an unscheduled consultation in order to prescribe drug treatment, and/or to prescribe additional examinations, and/or to adapt the patient's oxygen therapy prescription. The Case Manager re-evaluates the situation at 48h and 96h if necessary and forwards the information to the pulmonologist.
Device: Boracare remote monitoring solution
Bora Band wristband measuring vital signs at home, Bora Connect platform for caregiver visualization and BVS3 early detection of COPD exacerbations
Demonstrate the superiority of remote monitoring with the Bora Care solution in patients with COPD and frequent exacerbations compared to conventional follow-up.
Number of hospital days for respiratory deterioration per patient over 12 months.
Time frame: 1 year
Evaluate the effect of the device on the number of hospitalizations per patient.
Number of hospitalizations within 12 months of implementation of Bora Care remote monitoring.
Time frame: 1 year
Evaluate the effect of the device on the average length of stay.
Average length of stay in hospital within 12 months of the implementation of Bora Care.
Time frame: 1 year
Assess the overall quality of life of patients at baseline and at the end of the trial. (1)
Score from CAT (Chronic Obstructive Pulmonary Disease Assessment Test) questionnaire to assess the quality of life collected at Day 0, M6, M12.
Time frame: 1 year
Assess the overall quality of life of patients at baseline and at the end of the trial. (2)
Score from Short Form 36 (SF36) quality of life assessment questionnaire to assess the quality of life collected at Day 0, M6, M12.
Time frame: 1 year
Assess the overall quality of life of patients at baseline and at the end of the trial. (3)
Score from EXACT E-RS (Evaluating Respiratory Symptoms) symptom assessment questionnaire to assess the quality of life collected at Day 0, M6, M12.
Time frame: 1 year
Assess the conformity of use of the Bora Care device.
Number of hours spent wearing the Bora Connect bracelet normalized by the total number of hours spent in the remote monitoring session, information collected via the Bora Care tool.
Time frame: 3 years
Assess the impact of the device on the organisation of care. (1)
Number and nature of emergency, resuscitation, consultations and teleconsultations with the pulmonologist or attending physician.
Time frame: 3 years
Assess the impact of the device on the organisation of care. (2)
Duration of emergency, resuscitation, consultations and teleconsultations with the pulmonologist or attending physician.
Time frame: 3 years
Assess the impact of the device on the organisation of care. (3)
Number and nature of follow-up examinations and new pathologies detected during follow-up.
Time frame: 3 years
Assess the impact of the device on the quality of support. (1)
Number and nature of prescribed pharmacological treatments and prescribed oxygen therapy.
Time frame: 3 years
Assess the impact of the device on the quality of support. (3)
Duration of prescribed pharmacological treatments and prescribed oxygen therapy.
Time frame: 3 years
Assess patient and caregiver satisfaction with the device. (1)
Subjective assessment by the patient of the device, the reassurance provided by the device, the assistance to resume physical activity provided by the device, obtained using satisfaction questionnaires at M6 and M12.
Time frame: 1 year
Assess patient and caregiver satisfaction with the device. (2)
Subjective assessment by the patient of the overall quality of follow-up obtained using a detailed questionnaire (Likert scale) and an open-ended question about possible improvements at M6 and M12.
Time frame: 1 year
Assess patient and caregiver satisfaction with the device. (3)
Subjective assessment by caregivers of the Bora Care solution's impact on patient care using questions about organizational impacts and improved quality of care provided by the device, obtained using a satisfaction questionnaire at M6 and M12.
Time frame: 1 year
Evaluate the performance of the warning device in the early detection of exacerbations.
The number and nature of the alerts issued by the Bora Care solution, the number and nature of the actions taken following the alert specified in the alert management tool in the Bora Connect tool.
Time frame: 3 years
Identify new markers of exacerbations or other clinical events.
Alert performance in detecting exacerbations and other medical events by calculating alert sensitivity and specificity.
Time frame: 3 years
Plan to share: No — Not applicable. Data are not intended to be shared with other researchers.
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Dec 2027, 37 months after the start.
Of 88 industry-sponsored interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's planned 37 months is above that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Biosency